Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Payables (2016 - 2025)

Voyager Therapeutics' Payables history spans 12 years, with the latest figure at $5.0 million for Q4 2025.

  • On a quarterly basis, Payables rose 25.45% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 25.45% increase, with the full-year FY2025 number at $5.0 million, up 25.45% from a year prior.
  • Payables hit $5.0 million in Q4 2025 for Voyager Therapeutics, up from $2.1 million in the prior quarter.
  • Over the last five years, Payables for VYGR hit a ceiling of $7.6 million in Q1 2024 and a floor of $574000.0 in Q4 2021.
  • Historically, Payables has averaged $2.5 million across 5 years, with a median of $2.3 million in 2022.
  • Biggest five-year swings in Payables: crashed 82.52% in 2021 and later skyrocketed 347.04% in 2022.
  • Tracing VYGR's Payables over 5 years: stood at $574000.0 in 2021, then skyrocketed by 347.04% to $2.6 million in 2022, then plummeted by 37.49% to $1.6 million in 2023, then surged by 149.13% to $4.0 million in 2024, then rose by 25.45% to $5.0 million in 2025.
  • Business Quant data shows Payables for VYGR at $5.0 million in Q4 2025, $2.1 million in Q3 2025, and $1.8 million in Q2 2025.